Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma

Leukopenia and selective CD4+ lymphopenia represent major adverse events associated with the use of temozolomide (TMZ), an oral alkylating agent incorporated in the treatment of glioblastoma (GBM). The increased risk of opportunistic infections, including those caused by Pneumocystis jiroveci and cy...

Full description

Bibliographic Details
Main Authors: Rodrigo Ramella Munhoz, Andrea Arvai Pereira Picarelli, Cristina Aparecida Troques Mitteldorf, Olavo Feher
Format: Article
Language:English
Published: Karger Publishers 2013-08-01
Series:Case Reports in Oncology
Subjects:
Pulmonary aspergillosis
Temozolomide
Glioblastoma
Opportunistic infections
Online Access:http://www.karger.com/Article/FullText/354429

Internet

http://www.karger.com/Article/FullText/354429

Similar Items